.jpg "Hui Chen, MD, PhD photo")
Associate Professor
MD Anderson Cancer Center
I am a board-certified pathologist specialized in Molecular Genetics Pathology and Breast Pathology. My research interest is to study actionable genetic alterations in advanced solid tumors and their predications for therapeutic intervention. I work with molecular diagnostic laboratory, breast pathology, and cytogenetics teams on various quality improvement projects to improve the overall performance of immunohistochemistry and genotype platforms including next-generation sequencing for clinical molecular diagnostics. I participate in multiple clinical test development/validations of biomarker testing for solid tumors. I am co-medical director of Clinical Trial Operation to oversee test validation and customized tests of novel biomarkers for clinical trials at MD Anderson and nationwide. The accurate interpretation of biomarkers in cases with borderline and conflicting results can be extremely challenging. I am interested in improving the interpretation accuracy of biomarkers i.e. ER, PR, HER2, PTEN and MET in cases with borderline and conflicting results using alternative test platform to guide treatment decision for personalized cancer therapy.